Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant
Status:
Completed
Trial end date:
2019-05-28
Target enrollment:
Participant gender:
Summary
This phase I trial studies the best dose and how well bendamustine works with standard
chemotherapy (fludarabine, rituximab) in treating participants with lymphoid cancers
undergoing stem cell transplant. Drugs used in chemotherapy, such as fludarabine,
bendamustine, and rituximab, work in different ways to stop the growth of cancer cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving chemotherapy before a stem cell transplant helps stop the growth of cancer
cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells.
When the healthy stem cells from a donor are infused into the participant, they may help the
participant's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
Sometimes, the transplanted cells from a donor can make an immune response against the body's
normal cells called graft versus host disease. Giving rituximab and methotrexate after the
transplant may stop this from happening.